Ovarian cancer, version 2.2013 - PubMed (original) (raw)

Practice Guideline

. 2013 Oct 1;11(10):1199-209.

doi: 10.6004/jnccn.2013.0142.

Ronald D Alvarez, Deborah K Armstrong, Robert A Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M Gershenson, Heidi J Gray, Ardeshir Hakam, Laura J Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A Matulonis, David M O'Malley, Richard T Penson, Matthew A Powell, Steven W Remmenga, Paul Sabbatini, Joseph T Santoso, Julian C Schink, Nelson Teng, Theresa L Werner, Mary A Dwyer, Miranda Hughes; National comprehensive cancer networks

Affiliations

• PMID: 24142821
• DOI: 10.6004/jnccn.2013.0142

Practice Guideline

Ovarian cancer, version 2.2013

Robert J Morgan Jr et al. J Natl Compr Canc Netw. 2013.

Abstract

These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.

PubMed Disclaimer

Similar articles

• Ovarian cancer, version 3.2012.
  Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network. Morgan RJ Jr, et al. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49. doi: 10.6004/jnccn.2012.0140. J Natl Compr Canc Netw. 2012. PMID: 23138163
• NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
  Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039. J Natl Compr Canc Netw. 2019. PMID: 31390583
• NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
  Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. Armstrong DK, et al. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. J Natl Compr Canc Netw. 2022. PMID: 36075393
• New issues in systemic therapy for ovarian cancer.
  Armstrong DK. Armstrong DK. J Natl Compr Canc Netw. 2013 May;11(5 Suppl):690-3. doi: 10.6004/jnccn.2013.0203. J Natl Compr Canc Netw. 2013. PMID: 23704245 Review.
• Diagnosis and management of epithelial ovarian cancer.
  Bhoola S, Hoskins WJ. Bhoola S, et al. Obstet Gynecol. 2006 Jun;107(6):1399-410. doi: 10.1097/01.AOG.0000220516.34053.48. Obstet Gynecol. 2006. PMID: 16738170 Review.

Cited by

• Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.
  Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell GL, Conrads T, Sood AK, Orr D, Holmes LM, Gevaert M, Crosswell HE, DesRochers TM. Shuford S, et al. Sci Rep. 2019 Aug 1;9(1):11153. doi: 10.1038/s41598-019-47578-7. Sci Rep. 2019. PMID: 31371750 Free PMC article.
• Expression Profiles of ID and E2A in Ovarian Cancer and Suppression of Ovarian Cancer by the E2A Isoform E47.
  Lee YJ, Nam EJ, Kim S, Kim YT, Itkin-Ansari P, Kim SW. Lee YJ, et al. Cancers (Basel). 2022 Jun 12;14(12):2903. doi: 10.3390/cancers14122903. Cancers (Basel). 2022. PMID: 35740568 Free PMC article.
• Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996-2014.
  Villanueva C, Chang J, Ziogas A, Bristow RE, Vieira VM. Villanueva C, et al. Cancer Epidemiol. 2020 Dec;69:101825. doi: 10.1016/j.canep.2020.101825. Epub 2020 Oct 3. Cancer Epidemiol. 2020. PMID: 33022472 Free PMC article.
• Impact of diabetes mellitus on epithelial ovarian cancer survival.
  Akhavan S, Ghahghaei-Nezamabadi A, Modaresgilani M, Mousavi AS, Sepidarkish M, Tehranian A, Rezayof E. Akhavan S, et al. BMC Cancer. 2018 Dec 12;18(1):1246. doi: 10.1186/s12885-018-5162-3. BMC Cancer. 2018. PMID: 30541490 Free PMC article.
• Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer.
  Tsuyoshi H, Tsujikawa T, Yamada S, Okazawa H, Yoshida Y. Tsuyoshi H, et al. EJNMMI Res. 2020 Oct 2;10(1):117. doi: 10.1186/s13550-020-00712-3. EJNMMI Res. 2020. PMID: 33006685 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Sheridan PubFactory

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal